J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)
Erin Furr Stimming, Victor Sung, Claudia Testa, Sandra Kostyk, Christopher A Ross, Ali Samii, Michael D Geschwind, Deborah Hall, Praveen Dayalu, Russell Lonser, Brad Elder, Paul S Larson, David L Cooper, Marcie Clarkin, Talaha M Ali, Ricardo E Dolmetsch, on behalf of the AMT-130-01 Investigators
Journal of Neurology, Neurosurgery & Psychiatry Sep 2022, 93 (Suppl 1) A95; DOI: 10.1136/jnnp-2022-ehdn.255
